Today in Biology — Aug 16

[THEO] Okay, picture this: the world of science is just… humming. Not just with experiments in labs, but with big, national-level pushes that are really going to reshape how we do biology. And today, we’re starting with something truly foundational.

[DR. MARA] Indeed, Theo. The Department of Energy’s Genesis Mission is rapidly taking shape. They just held their inaugural summit, gathering federal agencies, national labs, universities, and international partners. The headline here is 278 projects are now behind the U.S. AI for Science Strategy.

[THEO] Two hundred and seventy-eight projects! That's not just a mission, that's practically an armada. And the core idea is AI-driven science. So, for listeners who might hear "AI for science" and think, you know, just better data analysis, what does the DOE actually mean by this? What’s the big push?

[DR. MARA] It's much more ambitious than just analysis. The DOE is actively developing *science-specific* AI models, what they call "open-weight foundation models." They're soliciting information from organizations to provide these systems and the vast scientific datasets needed to pretrain or fine-tune them. The goal is to fundamentally change how scientific discovery happens—accelerating it by building AI that understands and can even help design experiments and interpret complex results across disciplines.

[THEO] So, it’s not just using existing AI tools; it's about building *new* AI, specifically engineered for the unique challenges and data types of scientific research. I mean, thinking about engineering biology, if you could have an AI suggest novel enzymatic pathways or optimize genetic circuits with unprecedented speed, that's… that's a whole different ballgame. It's like having a super-powered co-investigator.

[DR. MARA] Precisely. It changes the scale and speed at which we can hypothesize, test, and iterate. It's a strategic investment that recognizes the computational intensity of modern biology, particularly synthetic and engineering biology, where we're dealing with vast combinatorial spaces for design.

[THEO] Okay, so that’s a massive investment in the future. Flipping the coin a bit, let's talk about how the present is being funded. We've heard some chatter about shifts at the NIH.

[DR. MARA] Yes, there's been discussion recently regarding the NIH. They've begun to limit grant applications where the "primary function" is informing policymakers about the health effects of public policy. Effectively, if your research is primarily designed to influence policy decisions, it may no longer be prioritized for funding through their traditional mechanisms.

[THEO] That feels like a significant shift. If you’re a researcher focused on, say, the public health impact of a new environmental regulation or a food policy, and your work directly informs that policy, is the NIH essentially saying, "That's not our lane anymore"?

[DR. MARA] That appears to be the implication. It signals a narrowing of scope for NIH funding, focusing more squarely on basic biomedical research and direct health interventions, rather than the broader societal and policy implications of health science. It means researchers in that intersection will need to seek funding from alternative sources, which can be challenging.

[THEO] And speaking of alternative sources, ARPA-H, the Advanced Research Projects Agency for Health, is definitely stepping into some interesting spaces. We just saw news about a $26 million award.

[DR. MARA] That's right. ARPA-H has committed $26 million to a program focused on developing scalable cell-free DNA biomanufacturing. This is a significant investment into a critical area for engineering biology.

[THEO] Cell-free DNA biomanufacturing — that sounds incredibly powerful for anyone building biological systems. Dr. Mara, for those who might not be working in this exact space, what does "cell-free DNA biomanufacturing" mean in practical terms, and why is this $26 million investment so important for the field?

[DR. MARA] It means producing DNA without needing intact living cells. Traditionally, you might transform bacteria with a plasmid, grow them up, and then extract the DNA. Cell-free systems allow you to combine the necessary enzymes and reagents in a test tube to synthesize DNA directly. This is crucial because it offers unparalleled speed, purity, and scalability for producing genetic constructs. For engineering biology, where you're constantly designing and testing new genetic circuits or pathways, being able to rapidly, and cleanly, synthesize the DNA you need, outside the constraints of a living organism, is a major bottleneck remover. It accelerates the design-build-test cycle dramatically.